Katherine Stueland Sells 6,325 Shares of GeneDx Holdings Corp. (NASDAQ:WGS) Stock

GeneDx Holdings Corp. (NASDAQ:WGS) CEO Katherine Stueland sold 6,325 shares of the company’s stock in a transaction on Monday, April 29th. The stock was sold at an average price of $11.04, for a total transaction of $69,828.00. Following the sale, the chief executive officer now directly owns 75,869 shares of the company’s stock, valued at $837,593.76. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

Katherine Stueland also recently made the following trade(s):

• On Monday, March 18th, Katherine Stueland sold 8,559 shares of GeneDx stock. The stock was sold at an average price of $10.59, for a total transaction of $90,639.81.

GeneDx Stock Performance

Shares of NASDAQ WGS traded up $6.07 during mid-day trading on Tuesday, hitting $17.07. The company had a trading volume of 7,282,556 shares, compared to its average volume of 325,185. GeneDx Holdings Corp. has a 12 month low of $1.16 and a 12 month high of $18.24. The company has a debt-to-equity ratio of 0.23, a current ratio of 3.10 and a quick ratio of 2.95. The firm has a market cap of $444.67 million, a P/E ratio of -2.25 and a beta of 2.75. The business’s 50-day simple moving average is $9.39 and its 200-day simple moving average is $5.09.

GeneDx (NASDAQ:WGS) last announced its quarterly earnings data on Tuesday, February 20th. The company reported ($0.59) EPS for the quarter, topping analysts’ consensus estimates of ($0.60) by $0.01. The company had revenue of $57.42 million during the quarter, compared to the consensus estimate of $57.00 million. GeneDx had a negative return on equity of 49.64% and a negative net margin of 86.77%. As a group, analysts predict that GeneDx Holdings Corp. will post -2.02 earnings per share for the current fiscal year.

Institutional Investors Weigh In On GeneDx

Several institutional investors and hedge funds have recently bought and sold shares of WGS. Oracle Investment Management Inc. grew its stake in shares of GeneDx by 14.9% in the 3rd quarter. Oracle Investment Management Inc. now owns 994,580 shares of the company’s stock valued at $3,620,000 after purchasing an additional 128,731 shares during the period. HighTower Advisors LLC boosted its stake in GeneDx by 14.1% in the 3rd quarter. HighTower Advisors LLC now owns 237,948 shares of the company’s stock valued at $865,000 after buying an additional 29,361 shares in the last quarter. Trellus Management Company LLC grew its position in GeneDx by 55.0% in the third quarter. Trellus Management Company LLC now owns 155,012 shares of the company’s stock valued at $564,000 after acquiring an additional 54,976 shares during the period. Decheng Capital LLC acquired a new position in GeneDx during the fourth quarter worth $285,000. Finally, Pathstone Family Office LLC lifted its holdings in shares of GeneDx by 262.2% during the third quarter. Pathstone Family Office LLC now owns 54,327 shares of the company’s stock valued at $198,000 after acquiring an additional 39,327 shares during the period. Institutional investors own 61.72% of the company’s stock.

Analyst Ratings Changes

WGS has been the topic of a number of recent analyst reports. TD Cowen lifted their price objective on GeneDx from $14.00 to $24.00 and gave the stock a “buy” rating in a research note on Tuesday. BTIG Research lifted their price target on GeneDx from $15.00 to $19.00 and gave the stock a “buy” rating in a research report on Tuesday. Finally, The Goldman Sachs Group upped their price target on GeneDx to $11.00 and gave the stock a “neutral” rating in a report on Monday, April 15th.

About GeneDx

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.